At 44.9% CAGR, the Europe Enzymatic DNA Synthesis Market is projected to be worth US$ 727.79 million by 2028, says Business Market Insights

According to Business Market Insights research, the Europe enzymatic DNA synthesis market  was valued at US$ 78.55 million in 2022 and is expected to reach US$ 727.79 million by 2028, registering a CAGR of 44.9% from 2022 to 2028. Rising prevalence of genetic disorders and surging number of product launches are the critical factors attributed to the Europe enzymatic DNA synthesis market expansion.        

Enzymatic approaches are the most attractive and are scalable, stereospecific, and environmentally benign. Enzymes can mediate mismatch recognition, enabling selective annealing of complementary strands, reducing the number of steps in each elongation cycle by eliminating the need for coupling reagents, and lowering the dependence on organic solvents. The enzymatic synthesis is inherently simpler than the chemical alternative and has the crucial potential to be much more precise than the chemical approach, introducing fewer errors into the code. This makes it possible to produce much longer sequences without causing cumbersome, inefficient, costly cleanups or workarounds. Several start-up companies and academic institutes are developing novel enzyme-based DNA synthesis technologies, which are believed to be the first breakthrough in DNA synthesis technology in ~40 years. These methods would significantly reduce costs and production time. As several enzyme companies are now active in the enzymatic DNA synthesis space, different business models have emerged with an increasing focus on DNA assembly and benchtop printers, creating opportunities for the enzymatic DNA synthesis market. DNA Script offers the Syntax instrument as a benchtop DNA synthesizer in a similar size as a HiSeq sequencer developed by Illumina. This synthesizer can generate 60 bp oligonucleotides in pure form for immediate use within 6 hours. In addition, the next generation of on-demand DNA synthesizers is likely to provide unprecedented accuracy, scalability, and speed, democratizing access to this technology and realizing the full promise of synthetic DNA to accelerate the development of tomorrow's medicine. These projected developments in the DNA synthesis landscape are expected open new opportunities for companies operating in the Europe enzymatic DNA synthesis market.

On the contrary, high cost and complex procedures hampers the Europe Enzymatic DNA Synthesis Market

Based on product type, the Europe enzymatic DNA synthesis market is segmented into custom DNA synthesis and DNA library synthesis. The DNA library synthesis held 57.3% share of Europe Enzymatic DNA Synthesis Market in 2022, amassing US$ 44.98 million. It is projected to garner US$ 405.88 million by 2028 to expand at 44.3% CAGR during 2022–2028. 

Based on application, the Europe enzymatic DNA synthesis market is segmented into synthetic biology, genetic engineering, therapeutic antibodies, vaccine design, and others. The synthetic biology segment held 52.3% share of Europe Enzymatic DNA Synthesis Market  in 2022, amassing US$ 41.05 million. It is projected to garner US$ 375.11 million by 2028 to expand at 44.6% CAGR during 2022–2028.

Based on technology, the Europe enzymatic DNA synthesis market is segmented into SOLA, CRISPR, PCR, and others. The PCR segment held 47.8% share of Europe Enzymatic DNA Synthesis Market  in 2022, amassing US$ 37.56 million. It is projected to garner US$ 341.53 million by 2028 to expand at 44.5% CAGR during 2022–2028.

Based on end user, the Europe enzymatic DNA synthesis market is segmented into academic & research institutes, biotech & pharmaceutical companies, diagnostic laboratories, and others. The biotech and pharmaceutical companies segment held 54.6% share of Europe Enzymatic DNA Synthesis Market  in 2022, amassing US$ 42.92 million. It is projected to garner US$ 393.45 million by 2028 to expand at 44.7% CAGR during 2022–2028.

Based on country, the Europe enzymatic DNA synthesis market  has been categorized into the U.K., Germany, France, Italy, Spain, and the Rest of Europe. Our regional analysis states that Germany captured 29.5% share of Europe Enzymatic DNA Synthesis Market  in 2022. It was assessed at US$ 23.13 million in 2022 and is likely to hit US$ 209.53 million by 2028, exhibiting a CAGR of 44.4% during the forecast period.      

Key players dominating the Europe enzymatic DNA synthesis market are Camena Bio; DNA Script; Evonetix; GenScript Biotech Corporation; Synbio Technologies; Telesis Bio Inc; Touchlight; and Twist Bioscience, among others.   

• In Feb 2023, Evonetix has completed a US$24 million financing round, extending its entire series B funding to over US$54 million. Existing investor Foresite Capital led the fundraising and others. The investment will enable the continued development of Evonetix’s semiconductor chips on a commercial scale.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com